InflaRx N.V. (IFRX)
| Market Cap | 156.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -53.25M |
| Shares Out | 26.00M |
| EPS (ttm) | -1.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $5.89 |
| Previous Close | $5.56 |
| Change ($) | 0.33 |
| Change (%) | 5.85% |
| Day's Open | 5.76 |
| Day's Range | 5.71 - 6.07 |
| Day's Volume | 286,204 |
| 52-Week Range | 2.65 - 8.96 |
JENA, Germany, Jan. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system...
JENA, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement s...
JENA, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system...
With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 ...
JENA, Germany, Oct. 29, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system...
It wasn't just toilet paper that was in demand when Covid-19 hit us as short-term stocks flew through the roof. But with a second wave upon us, this narrative looks very compelling.
JENA, Germany, Sept. 17, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement sys...
JENA, Germany, Sept. 14, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement sys...
JENA, Germany, July 30, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement syst...
Investors need to pay close attention to InflaRx (IFRX) stock based on the movements in the options market lately.
JENA, Germany, July 21, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement syst...
InflaRx has been struggling lately, but the selling pressure may be coming to an end soon.
JENA, Germany, June 17, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement syst...
InflaRx (IFRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Europe stocks rally on hopes that the European Union will unveil large stimulus package to reduce the economic fallout from the coronavirus pandemic.
JENA, Germany, May 21, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement syste...
InflaRx N.V. (NASDAQ: IFRX) shares jumped early on Wednesday after the company announced that it has enrolled its first patient into a clinical trial for the treatment of severe COVID-19-induc...
JENA, Germany, March 31, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complemen...
JENA, Germany, Feb. 26, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement...
InflaRx Tanks 91.79% As IFX-1 Phase II Trial Flops, Provides Bargain Buy For Competitor ChemoCentryx
InflaRx's drug IFX-1 performed equal or worse in patient groups compared to a placebo in Phase II clinical trial for skin disorder Hidradentis Suppurativa.
Shares of the thinly traded, micro-cap biotech Inflarx NV (NASDAQ: IFRX) were losing 90 percent of their value Wednesday following a failed clinical trial.
InflaRx N.V. shares were destroyed on Wednesday after the firm announced results from its midstage trial in patients suffering from moderate to severe hidradenitis suppurativa (HS).
Shares of InflaRx fell 84% in premarket trade Wednesday after the biotech said its drug for an inflammatory skin disorder called hidradenitis suppurativa failed to show a statistically signif...
InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 30.65% and -100.00%, respectively, for the quarter ended March 2019.
InflaRx (IFRX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
About IFRX
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammat... [Read more...]
| Industry Biotechnology | IPO Date Nov 8, 2017 |
| CEO Dr. Niels C. Riedemann M.D., Ph.D. | Employees 43 |
| Stock Exchange NASDAQ | Ticker Symbol IFRX |
Analyst Forecasts
According to 7 analysts, the average rating for InflaRx N.V. stock is "Hold." The 12-month stock price forecast is 9.68, which is an increase of 64.49% from the latest price.